FDA
-
-
-
-
-
-
-
Alexion to Acquire Portola
-
-
-
-
-
-
-
Portola Announces Preliminary Full Year 2019 Andexxa Global Net Revenues of Approximately $111 Million
-
-
-
-
-
-
-
Portola Pharmaceuticals to Present Multiple Abstracts at the 61st American Society of Hematology (ASH) Annual Meeting
-
-
-
-
-
-
-
Portola Pharma (PTLA) Reports New In Vitro Data at ISTH 2019 Meeting
-
-
-
-
-
-
-
European Commission Grants Conditional Marketing Authorization for Portola Pharmaceuticals’ Ondexxya™ (andexanet alfa), the First and Only Antidote for the Reversal of Factor Xa Inhibitors
-
-
-
-
-
-
-
Portola Pharma (PTLA) Enters into $125 Million Loan Agreement with HealthCare Royalty Partners and Athyrium Capital Management
-
-
-
-
-
-
-
Portola Pharmaceuticals to Present Full Results from the ANNEXA-4 Study of Andexxa During a Late-Breaking Oral Presentation at the International Stroke Conference 2019
-
322,312 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

